15th Conference on Retroviruses and Opportunistic Infections

HIV Treat Bull - 2008 March-April;9(3/4):

Introduction

This annual conference is one of the most important annual scientific meetings.

Abstracts for the meeting are online as soon as the conference opens, and many of the most important oral abstract sessions and overview sessions are posted as webcasts within a day or so. We encourage readers to go directly to the source for many of these sessions

This issue includes reports on antiretrovirals and treatment strategies, prevention of mother to child transmission (PMTCT), hepatitis coinfection and oncology:

• Atazanavir/r vs lopinavir/r in treatment-naïve patients: 48 week results
• Baseline inflammation and coagulation markers and changes over four weeks during a treatment interruption are strongly linked to HIV viraemia and risk of mortality
• Restarting treatment after an interruption reduces the risk of serious events but CD4 recovery falls short of baseline
• Very low rate of MTCT in women on HAART in UK and Ireland who achieve viral suppression
• Predictors of mother to child transmission among women initiating HAART in pregnancy in a South African cohort
• Maternal and infant outcomes from the DREAM programme
• Nevirapine-resistant HIV present in the latent reservoir following single-dose nevirapine for MTCT prevention
• Tenofovir plus FTC reduce NNRTI resistance following single dose nevirapine
• Response to treatment after single dose NVP exposure in women
• Response to treatment after single dose NVP exposure in infants
• Other studies looking at birth outcomes
• Infant prophylaxis for postnatal transmission
• Antiretroviral drug concentrations in breast milk and breastfeeding infants
• Maternal breastfeeding prophylaxis
• Risk factors for breastfeeding transmission
• UK cohort reports sexual HCV reinfection in at least 5% HIV-positive gay men following sustained response to treatment
• MELD score predictive of pre-transplant mortality in HIV/HCV coinfected patients
• Does abacavir decrease SVR rates with HCV treatment?
• No effect of interferon maintenance therapy on fibrosis progression in non-responders
• Stem cell transplant from HLA-matched CCR5-delta 32 deleted donor suppresses viraemia in recipient for eight months without HAART
• Risk factors for AIDS-defining and non AIDS-defining cancers Further coverage will be included in subsequent issues of HTB.

Further coverage will be included in subsequent issues of HTB.

2008-03-10
IB080903-02

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.